J&JPRD Files Schizophrenia Drugs

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted multiple applications to the FDA for the treatment of schizophrenia.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted multiple applications to the FDA for the treatment of schizophrenia. The company submitted its response to the FDA complete response letter for paliperidone palmitate, an investigational once-monthly atypical antipsychotic injection. If approved, the drug will be indicated for the acute and maintenance treatment of schizophrenia. The company also submitted two sNDAs requesting approval for t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters